Results 81 to 90 of about 2,143 (210)

A contemporary examination of the effect of driver training for reducing crash risk in novice adolescent drivers: protocol for the DRIVER study, a random assignment trial. [PDF]

Inj Epidemiol
Walshe EA, Romer D, Elliott MR, Baxelbaum KS, Delgado MK, Ebert JP, Winston FK.   +6 more
europepmc   +1 more source

Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies

Advanced Science, EarlyView.
This study presents a 3D embedded bioprinting platform that recapitulates key stromal features of the tumor microenvironment using fibroblasts and lung‐derived ECM. The model enables functional assessment of CAR‐NK cells and provides a versatile tool to support the development of next‐generation immunotherapeutic strategies against solid tumors ...
Dahong Kim, Seona Jo, In‐Hwan Jang, Yu‐Jin Kim, Youngmee Jung, Junhyoung Ahn, Hyungjun Lim, Jae Jong Lee, Kangwon Lee, Tae‐Don Kim, Su A Park   +10 more
wiley   +1 more source

Assessing the American public's preferences for reforms to teen driving licensure systems: a discrete choice experiment. [PDF]

Inj Prev
Drabo EF, Michael JP, Ehsani JP.
europepmc   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

Development and validation of a sensor-integrated smart driving test system for automated, scalable, and objective driver performance evaluation. [PDF]

Sci Rep
Sabry ES, Wagdy KE, Elkholy YM, Farid MA, Domdom FM, Mohamed MA, Abdelkhalik AA, Alshathri S, El-Shafai W.   +8 more
europepmc   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

A multimodal approach for assessing the risk of cervical spine injury in low-speed rear-end collisions: kinematic and clinical responses. [PDF]

Front Bioeng Biotechnol
Lee HY, Lee KH, Kim OH, Kim H, Kang CY, Kim GH, Kim NH, Youk H.   +7 more
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Detecting automobile insurance fraud using a novel penalty-driven feature selection method with particle swarm optimization and machine learning classifiers. [PDF]

Sci Rep
Özaltın Ö, Erdemir ÖK.
europepmc   +1 more source

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source